Prescription Drugs · Oncology Therapeutics
AstraZeneca: Products & infrastructure
AstraZeneca has 1 apps in the stores: 0 ratings and 5k+ downloads on Google Play.
Data updated Nov 21, 2026 · Back to the company report
Products
AstraZeneca has 1 apps in the stores: 0 ratings and 5k+ downloads on Google Play.
5k+Google Play downloads
1Apps
5Products on its site
$684.9Mpaid to US doctors in 2025
FDA approvalsnew drugs, biologics and high-risk devices, per Drugs@FDA and PMA · and 100 more records
Breztri Aerosphere
New drug (NDA) · NDA220290 · budesonide, formoterol fumarate, glycopyrrolate · inhalation
Oct 2026
Sep 2026
Jul 2026
May 2026
Apr 2026
Sep 2025
Wainzua
EU authorisation (EMA) · EMEA/H/C/006295 · eplontersen sodium · Amyloid Neuropathies, Familial
Mar 2025
Kavigale
EU authorisation (EMA) · EMEA/H/C/006291 · sipavibart · COVID-19 virus infection
Jan 2025
EU clinical trialsthe trials it sponsors, per the EU's CTIS register
A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combinations in Adult Patient…
Therapeutic exploratory (Phase II) · TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) · Poland, France, Italy
Nov 2026
A Randomised, Double‑Blind, Placebo‑Controlled, 2‑Cohort, Phase III Study of Saruparib Combined with Physician’s Choice…
Therapeutic confirmatory (Phase III) · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · Poland, Hungary, France, Austria, Germany, Spain,…
Oct 2026
ROSY-S: Rollover Study for Participants Who have Completed a Previous Study with Anifrolumab (Saphnelo) and Are Assesse…
Therapeutic confirmatory (Phase III) · Systemic Sclerosis
Cutaneous Lupus Erythematosus
Myopathies… · Netherlands, Belgium, Bulgaria, Romania, Italy, G…
Oct 2026
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared with Dapagli…
Therapeutic confirmatory (Phase III) · Renal Insufficiency, Chronic · France, Germany, Austria, Poland, Romania, Italy,…
Oct 2026
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD62…
Therapeutic confirmatory (Phase III) · Obesity or Overweight,
Weight-Related Comorbidity,
without … · Italy, Czechia, Germany, Bulgaria, France, Poland
Oct 2026
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Du…
Therapeutic confirmatory (Phase III) · Newly Diagnosed Multiple Myeloma · Germany, Spain, Norway, Italy, Denmark, France, P…
Oct 2026
Payments to US doctorsCMS Open Payments - the maker's totals, no recipient
$684.9M
$555.3M
$537.8M
Compensation For Services Other Than Consulting, Including S
a kind of payment, 2025
$29M
$15.7M
$13.5M
$11.4M
$10.5M
$7.1M
Clinical trialsthe studies it sponsors or works on, per ClinicalTrials.gov · and 3,642 more records
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
under way · 3,000 participants · Lung Cancer
Apr 2027
Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Form…
under way · 200 participants · Asthma; Uncontrolled Asthma; Asthma-COPD Overlap
Jan 2027
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Ove…
phase 3 · under way · 330 participants · Obesity; Overweight; Type 2 Diabetes Mellitus
Jan 2027
Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence
under way · 1,500 participants · Lung Cancer
Dec 2026
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreat…
phase 3 · under way · 1,200 participants · Large B-cell Lymphoma
Dec 2026
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and P…
phase 3 · under way · 204 participants · Hypercholesterolemia
Dec 2026
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC
under way · 78 participants · Carcinoma, Non-Small-Cell Lung
Nov 2026
A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma
under way · 532 participants · Lymphoma, B-Cell
Nov 2026
Apps
Google Play · 5k+ downloads · AstraZeneca Pharmaceuticals LP
Products named on its site
Tagrisso
A targeted therapy for non-small cell lung cancer with EGFR mutations. It is one of the company's largest selling medicines.
Farxiga
An SGLT2 inhibitor used across diabetes, heart failure and chronic kidney disease. Its indications expanded well beyond the original diabetes use.
Enhertu
An antibody drug conjugate for breast and other cancers, developed with Daiichi Sankyo. It has reshaped treatment in several tumour types.
Imfinzi
A checkpoint inhibitor used across lung, bladder and liver cancers. It anchors the immuno-oncology part of the portfolio.
Alexion Rare Disease
Complement inhibitors and other rare disease medicines acquired in 2021. The unit operates as a distinct business within the group.
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Infrastructure
AstraZeneca holds 3 MW of generating capacity in 1 US power plants (EIA-860, 2025).
3 MWUS generating capacity
1US power plants
Power plantsEIA-860
AstraZeneca Newark Solar
DE · Solar Photovoltaic · operator AstraZeneca Pharmaceuticals · eia.gov ↗
3 MW
Power plants: EIA-860 - the operating utility holds a solely owned generator, each owner its percent of a jointly owned one; nameplate capacity of operable generators; each plant links its EIA page.
